• The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb.
• OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
• Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages the company’s proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs.
• VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.
• The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
• VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.

VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.

The announcement marks the successful completion of the discovery portion of VERAXA’s collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies.